Business Context and Reporting Period
This Form 8-K is filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) on March 17, 2022. The filing serves to announce the results of operations for the fourth quarter and full year ended December 31, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It directs readers to the referenced press release for the comparative analysis of the fourth quarter and full-year 2021 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished pursuant to Item 2.02, including the press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities under that section and shall not be deemed incorporated by reference into any other filings under the Securities Act or Exchange Act. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated March 17, 2022).
- Confirm the company name is Virios Therapeutics, Inc., noting the discrepancy with the metadata label "Dogwood Therapeutics, Inc."
- Review the press release for any forward-looking statements or clinical trial updates not captured in this summary.
- Check the company's status as an emerging growth company (indicated as "Yes" in the filing) for potential differences in financial reporting standards.